Retension Pharmaceuticals (NASDAQ:RTSN) Stock Rating Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Retension Pharmaceuticals to “hold.” Despite the upgrade, analyst consensus remains “buy,” with a $52.50 average price target.
• Recent analyst coverage includes ratings ranging from hold to strong buy; Guggenheim set a $55 target and Oppenheimer set a $50 target.
• CEO Eric L. Keller and director Franklin M. Berger each bought shares at $12 per share, purchasing 20,800 and 10,000 shares, respectively.

Retension Pharmaceuticals (NASDAQ:RTSN - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities analysts have also issued reports on the stock. Zacks Research began coverage on shares of Retension Pharmaceuticals in a research report on Wednesday, November 4th. They set a "hold" rating for the company. Guggenheim assumed coverage on shares of Retension Pharmaceuticals in a report on Monday, November 2nd. They issued a "buy" rating and a $55.00 price objective on the stock. Leerink Partners initiated coverage on shares of Retension Pharmaceuticals in a research note on Tuesday, November 3rd. They issued a "strong-buy" rating on the stock. Finally, Oppenheimer initiated coverage on shares of Retension Pharmaceuticals in a research note on Tuesday, November 3rd. They issued an "outperform" rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Retension Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $52.50.

Retension Pharmaceuticals Stock Up 0.2%

Retension Pharmaceuticals stock opened at $12.27 on Friday. Retension Pharmaceuticals has a 52 week low of $9.66 and a 52 week high of $18.64.

Insider Transactions at Retension Pharmaceuticals

In related news, CEO Eric L. Keller bought 20,800 shares of the company's stock in a transaction that occurred on Tuesday, October 13th. The shares were purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the completion of the acquisition, the chief executive officer directly owned 423,377 shares in the company, valued at approximately $5,080,524. The trade was a 5.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Franklin M. Berger purchased 10,000 shares of Retension Pharmaceuticals stock in a transaction that occurred on Tuesday, October 13th. The shares were bought at an average price of $12.00 per share, with a total value of $120,000.00. Following the completion of the transaction, the director owned 10,000 shares of the company's stock, valued at $120,000. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.